Introduction
The ability of the HIV-1-based lentiviral vector (LV) to deliver genes into hematopoietic stem cells holds great promise for the treatment of infectious diseases like acquired immune deficiency syndrome (AIDS), and hereditary hematopoietic disorders like severe combined immune deficiency. The main potential risk of gene transfer using integrating viral vectors is insertional mutagenesis resulting from random integration into the host cell genome. This became evident after the recent development of T-cell leukemia in three patients with X-linked severe combined immune deficiency in a gene therapy trial using a retroviral vector. 1, 2, 3 These studies indicate that extensive preclinical experiments in large animal models are required to evaluate the safety of the transfer vector and the therapeutic transgene during a long-term follow-up. Old World monkeys like rhesus macaque would be an adequate model for gene therapy safety studies using HIV-1-based LVs. However, it was observed that Old World monkeys posses an antiviral defense mechanism that restricts retroviruses. 4, 5, 6, 7, 8 The cellular factor involved in this restriction was initially named Lv-1, and later identified as the tripartite interaction motif 5α (Trim5α). 9 This antiviral activity appeared to be species-specific and was shown to block infection of a broad range of retroviruses. 9, 10, 11, 12, 13, 14 Trim5α obtained from different Old World monkey species were particularly effective in restricting HIV-1. Another cellular factor involved in early post-entry steps in HIV-1 infection is Cyclophilin A (CyPA). CyPA interacts specifically with the CyPA-binding region of the HIV-1 group M capsid protein and is encapsidated into the virions. 15, 16, 17, 18 However, HIV-1 virions produced in the absence of CyPA are infectious, demonstrating that packaging of CyPA is not required for virus replication. This indicates that CyPA present in the target cells is sufficient to support infection. 19, 20 Although most group M HIV-1 viruses require CyPA for replication, naturally occurring variants carrying amino-acid substitutions in the CyPA-binding region that render replication in human cells independent of CyPA have been identified. 19, 21 HIV-1 group O viruses are phylogenetically and distantly related to HIV-1 group M viruses, and it is thought that they originate from a separate zoonosis of simian immunodeficiency virus (SIV) CPZ . 22 Similar to HIV-1 group M viruses, HIV-1 group O viruses incorporate CyPA; however, infection of these viruses is not dependent on CyPA. 23 Another lentivirus reported to be able to replicate independent of CyPA is HIV-2. 24 HIV-2 originates from a cross-species transmission of SIV smm 25 and unlike HIV-1 the capsid protein is unable to interact with CyPA. 24 The mechanism by which CyPA supports HIV-1 infection remains unclear. Some reports suggest that CyPA protects HIV-1 from antiviral factors like Trim5α, 20, 26, 27, 28, 29 whereas others have suggested that CyPA facilitates disassembly of the viral capsid. 30, 31, 32 Previously, we and others demonstrated that the CyPA-binding region of the HIV-1 capsid protein is the viral determinant involved in the postentry restriction in Old World monkey cells and that mutations in this region increased the transduction efficiency in these cells. 19, 33, 34, 35 Furthermore, we observed that escape from the restriction coincided with CyPA-independent transduction in human cells. 19 Here, we constructed HIV-1-based LVs that can efficiently transduce Old World monkey cells. We studied the amino acids of the CyPA-binding region of HIV-1 group M, group O, and HIV-2 viruses that are required for efficient transduction of simian cells and analyzed the role of CyPA in the observed restriction in simian cells. We observed that amino-acid changes in the CyPA-binding region that have previously been shown to reduce CyPA-binding affinity were able to overcome the restriction in simian cells.
Results
Resistance of HIV-1-based LV post-entry restriction in simian cells by a single amino-acid change in the CyPA-binding region of capsid
The HIV-1-based LV is derived from an HIV-1 group M virus. 36, 37, 38 Recently, we demonstrated that substitution of the CyPA-binding region of the LV capsid protein by that of the macrophage tropic HIV-1 Ba-L (gB) was able to escape the post-entry restriction in simian cells. 19 The
CyPA-binding region of the HIV-1 Ba-L variant contains three amino-acid differences (glutamine 87, proline 88, and valine 91) as compared with the wild-type (WT) HIV-1 HxB2. Here, we analyzed which of these amino-acid residues is responsible for the observed resistance of HIV-1-based LVs to restriction in simian cells. We constructed three additional mutant LVs (Table 1) that contained a valine at position 91 (HM.1), a glutamine at position 87 and a valine at position 91 (HM.2), or a proline at position 88 (HM.3). Green fluorescent protein (GFP)-expressing mutant LV were produced and their infectivity was analyzed in human 293T cells, African green monkey kidney cell line CV-1, and the rhesus macaque fibroblast line FrhL2. Similar to our previous observations, 19 we observed that infection with low dose of WT was restricted in the simian cell lines CV-1 and FrhL2, and that restriction could be saturated by infection with high amounts of virus. Moreover, gB was not restricted in simian cells and efficiently infected CV-1 and FrhL2 cells (Figure 1a) . HM.1, HM.2, and HM.3 were able to infect 293T cells efficiently, although some variation in the infectious virus titers was observed. HM.1 showed consistently a slight increase in the infectious titer per nanogram p24, whereas HM.2 showed a slight decrease in the infectious titer compared with WT and gB. Similar to WT, HM.1 was restricted in simian cells (Figure 1a ), indicating that a valine at position 91 is not sufficient for overriding the post-entry restriction in simian cells. A phenotype similar to gB was observed for HM.2 and HM.3. These were not restricted in CV-1 and FrhL2 (Figure 1a) , indicating that either a glutamine at position 87 or proline at position 88 results in efficient transduction of simian cells. In our previous study, 19 
CyPA-independent infection of chimeric HIV-1 group O LV is not associated with unrestricted infection of simian cells
To analyze whether CyPA-independent infection of HO.1 virus was associated with unrestricted infection of simian cells, we constructed a chimeric HIV-1 group O LV containing the CyPA-binding region of the HIV-1 group O variant MVP-5180 (HO.1) ( Table 1) . First, we confirmed that HO.1 was indeed able to infect human cells independent of CyPA by showing a lack of effect of the CyPA inhibitor CsA (1 µg/ml) on infection of 293T cells ( Figure 2a ). Next, infectivity of HO.1 was analyzed in simian CV-1 and FrhL2 cells. In contrast to our previous observations in HIV-1 group M LVs, the CyPA-independent phenotype of HO.1 was not associated with unrestricted infection in simian cells and reduced infectivity was observed in CV-1 and FrhL2 cells ( Figure 2b ). To analyze whether infection of simian cells with HO.1 was restricted by the same cellular factor as WT, coinfection experiments were performed to saturate the inhibitory cellular factor using WT or HO.1-expressing LacZ. We observed that GFP expression from both HO.1 and WT could be enhanced by coinfection with WT or HO.1 in FrhL2 ( Figure 2c ) and CV-1 cells, respectively (data not shown), indicating that the same cellular factor is involved in the post-entry restriction of both LVs in simian cells. In this study, we observed that amino acids proximal to the CyPAbinding residues (glycine at position 89 and proline at position 90 16, 18 ) are critical in the observed restriction in simian cells and that amino-acid changes at these positions can circumvent restriction. To analyze whether the post-entry restriction in simian cells of HO.1 in simian cells could also be reversed by mutations at these positions, additional mutant LVs were constructed. When the proline at position 86 of HO.1 was replaced by a valine (HO.2) ( Table 1) , we observed that this LV was still restricted in simian cells comparable to the parental LV (Figure 2d ). However, when we additionally replaced methionine at position 88 with a proline (HO.3) (Table 1) , the LV became resistant to the inhibitory factor and were able to infect CV-1 and FrhL2 efficiently (Figure 2d ).
Resistance of HIV-1-based LVs from restriction in simian cells by the CyPA-binding region of HIV-2
To analyze whether the CyPA-independent replication of HIV-2 was associated with an unrestricted infection of simian cells, the region in the capsid protein of HIV-2 ROD corresponding to the CyPA-binding region was placed into the HIV-1-based LV (H2.1) ( Table 1 ). H2.1 had reduced infectivity in human cells compared with WT. This reduced infectivity was not due to the presence of restricting cellular factors present in 293T cells, as coinfection experiments using high concentrations of H2.1 or WT-expressing LacZ did not increase GFP expression from H2.1 (data not shown). When 293T cells were infected with increasing concentration of H2.1 in the presence of CsA, we indeed observed that infection was independent of CyPA ( Figure 3a) . Next, we analyzed whether H2.1 was able to infect simian cells efficiently. 293T, CV-1, and FrhL2 cells were infected with increasing concentrations of H2.1, and GFP expression was analyzed at day 5. H2.1 efficiently infected simian cells (Figure 3b) , indicating that the LV containing the CyPA-binding region of HIV-2 escapes the restriction in simian cells. (Table 1 ) and infectivity was analyzed in 293T, CV-1, and FrhL2 cells. When the proline at position 88, or the isoleucine at position 87 were replaced respectively by an alanine (H2.2) or a histidine (H2.3), the phenotype of the LV did not change and high infectivity for both mutants was observed in CV-1 and FrhL2 (Figure 3c ). Even when both amino acids were replaced simultaneously (H2.4), CV-1 and FrhL2 cells were infected with efficiency comparable to infection of 293T cells (Figure 3c ). The HIV-2 CyPA-binding region lacks one amino acid compared with WT. To analyze whether the length of the CyPAbinding region is important for the non-restricted phenotype observed for H2.1-H2.4, an additional valine was introduced (H2.5). When H2.5 was used to infect 293T cells, we observed that the virus had increased infectivity and infectious titer compared with HO.1 and HO.2. Furthermore, we observed that H2.5 infection was independent of CyPA, as CsA treatment did not affect infectivity in 293T cells (data not shown). Next, we analyzed whether H2.5 was able to infect simian cells. Compared with infection of 293T cells, infection of CV-1 and FrhL2 was reduced (Figure 3c ), indicating that H2.5 was restricted in simian cells. To confirm that H2.5 was restricted by the same cellular factor restricting WT, coinfection experiments were performed. We observed that GFP expression from either H2.5 or WT was enhanced by coinfection with respectively WT or H2.5 in FrhL2 (Figure 3d ) and CV-1 cells (data not shown), indicating that the similar cellular factor is responsible for the observed post-entry restriction in simian cells.
Role of CyPA in the post-entry restriction of LVs in simian cells
Here, we observed that the CyPA-binding region of the capsid protein is involved in the post-entry restriction observed in simian cells. To analyze whether CyPA plays a role in post-entry restriction, we analyzed whether CsA treatment had an effect on viral infectivity in simian cells. 
Efficient transduction of rhesus macaque peripheral blood mononuclear cell (PBMC) by the HIV-1-based LV containing the CyPAbinding region of HIV-2
We observed efficient transduction of simian cells by several HIV-1-based vectors in FrhL2 and CV-1 cells. To analyze whether these mutant LV were also able to transduce primary rhesus macaque cells, the transduction efficiency of gB, HM.2, and H2.1 in PBMC obtained from rhesus macaque and human was compared. PBMCs obtained from two rhesus macaques and two human donors were inoculated at a multiplicity of infection of 10 for gB and HM.2 and 5 for H2.1. For comparison, rhesus macaque PBMC and human PBMC were inoculated with WT and HO.1 at a multiplicity of infection of 10. At day 6 postinoculation, FACS analysis revealed that all HIV-1-based LVs efficiently transduced human PBMC ( Figure 5 ). As expected, rhesus macaque PBMC were resistant to transduction with WT and HO.1. However, gB and HM.2, which were able to transduce FrhL2 and CV1 cells efficiently, were restricted in primary rhesus macaque PBMC ( Figure 5 ). In contrast, transduction of H2.1 in rhesus macaque PBMC was not restricted ( Figure  5 ), indicating that this vector is able to circumvent the antiviral activity present in primary rhesus macaque cells. 16, 18, 39 In addition, residues in close proximity to the central proline contribute to the binding interaction. 31, 40, 41 Based on our results, mutant LVs could be divided into three groups (Table 2) . WT and HM.1 belong to the first group that are sensitive to CsA treatment of human cells and are restricted in simian cells. According to the available structural data, these LVs have a high affinity for CyPA. Replacement of the isoleucine at position 91 by a valine, as in HM.1, had no effect on the CyPA-capsid interaction. 40 LVs in the second group (Table 2) are not restricted in simian cells and are able to infect human cells in a CyPA-independent manner. In gB, HM.2, and HO.3, the histidine at position 87 is replaced with a glutamine or an alanine. Computational and theoretical studies have suggested that the histidine at position 87 makes energetically favorable contacts with CyPA. 42 Therefore, replacement of this residue might interfere with the CyPA-capsid interaction. Indeed, a fivefold reduction in the affinity for CyPA was observed when the histidine was replaced by a glutamine or an alanine. 40 HM.3 still contains the histidine at position 87; however, the alanine at position 88 is replaced by a proline. The methyl group of the alanine at position 88 also makes energetically favorable contacts with CyPA and replacement of this alanine reduced the affinity for CyPA. 40 Also belonging to this group are LVs that contain the CyPAbinding region of HIV-2 (H2.1-4), which is one amino acid shorter compared with WT. The length of the CyPA-binding loop has previously been described to be critical for the interaction between the capsid protein and CyPA, and the lack of a single amino acid might interfere with the capsid-CyPA interaction. 43 This is in agreement with the observation that HIV-2 virions are unable to incorporate CyPA. 23 These data imply that the CyPA-binding region in the second group of recombinant LVs share a low binding affinity for CyPA. (Table 2) .
Interestingly, we observed that HO.2 and H2.5 were able to escape restriction completely in simian cells by CsA treatment. This suggests a direct role for CyPA in Trim5α-mediated inhibition in simian cells, which is in agreement with earlier reports. 28, 29, 44, 45 In these studies, it was observed that CyPA downregulation using siRNA or disruption of the CyPA-capsid interaction by CsA enhanced infectivity of HIV-1 in simian cells. Concomitantly, we observed that reduction of binding affinity of the HIV-1 capsid for CyPA is associated with unrestricted infection of simian cells, which also indicates that CyPA is required for restriction of HIV-1 in Old World monkey cells.
CsA-dependent virus replication has been described previously. 17, 43, 46 Braaten et al. observed that replication of HIV-1 in which the alanine at position 92 was substituted by a glutamic acid or when glycine at position 94 was replaced by an aspartic acid became CsA-dependent in CEM and Hela CD4 cells. 17, 4646, 47 A similar observation was made by
Bukovsky et al. 43 for SIVmac that contained the HIV-1 CyPA-binding region up to position 90. The described CsA-dependent mutants contained mutations in the region distal to the proline at position 90 and it was suggested that mutation of amino-acid residues involved in the formation of the type II tight turn results in CsA-dependent virus replication. 17, 43, 46 The HO.2 and H2.5 LV also contain mutations distal to the proline at position 90. However, CsA-dependent infection in simian cells was not observed when an additional proline was present proximal to the proline at position 90 (HO.1 and HO.3) or when the CyPA-binding region was one amino acid shorter (H2. [1] [2] [3] [4] . This indicates that amino acids proximal to the CyPA-binding region can also influence CsAdependent infection.
Recently, it was observed that HIV-2 was restricted by Trim5 from rhesus macaques. 8, 14 We observed that the HIV-2 CyPA binding loop was able to convert the HIV-1 group M LV from a sensitive to a resistant virus in rhesus macaque and African green monkey cells. Although our data suggest that the CyPA binding region is involved in the observed restriction of group M HIV-1 in simian cells, it is not the primary determinant involved in the restriction of HIV-2. We observed that mutations in the CyPA-binding region can affect the infectious titer of LVs in human cells. In particular, reduced infectivity was observed for LVs that contains a HIV-2-like CyPA-binding region (H2.1-H2.4), which is one amino acid shorter compared with the other LVs. The reduced infectivity of these LVs was not due to the presence of saturable inhibitory factors as coinfection experiments did not increase the transduction efficiency. Therefore, it is more likely to assume that the short CyPA-binding region might affect the packaging and assembly process.
The transduction efficiency of gB, HM.2, and H2.1 was also evaluated in primary rhesus macaque PBMC. In contrast to our observations in FrhL2 and CV1 cells, only H2.1 was able to transduce rhesus macaque PBMC at levels comparable to human PBMC. Previously, we observed that the gB mutant LV was able to transduce hematopoietic stem cells obtained from baboon efficiently, 19 whereas this LV was restricted in primary rhesus macaque PBMC. Therefore, it cannot be excluded that other speciesspecific differences in cellular factors or cellular factors whose expression is dependent on the differentiation state of the cell population might be involved in the observed restriction of gB and HM.2 in rhesus macaque PBMC.
A major obstacle for gene therapy studies in non-human primates is the inefficient transduction owing to the presence of inhibitory factors like Trim5 . Therefore, the LVs in this study might be very useful to conduct long-term gene therapy studies in non-human primate models like rhesus macaques.
Materials and Methods
Cell cultures and production of HIV-1-based LVs. Human 293T cells, the African green monkey kidney cell line CV-1, and the rhesus macaque fibroblast line FrhL2 were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), antibiotic/antimycotic (Life Technologies, Rockville, MD).
The HIV-1-based LV pseudotyped with vesicular stomatitis virus glycoprotein envelope was used to analyze the effect of mutations in the capsid protein on the infectivity in 293T, CV-1, and FrhL2 cells. The LV production system consists of four constructs: LV-construct, which produces the viral RNA containing the cDNA sequence of GFP or LacZ under control of a cytomegalovirus promoter; the packaging construct encoding for gag/pol (packaging construct); the vesicular stomatitis virus glycoprotein-expressing construct (pcytomegalovirus-vesicular stomatitis virus glycoprotein); the HIV-1 rev-expressing construct (pRous sarcoma virus-rev). 37 LVs were produced by transient transfection in 293T cells using the calcium phosphate method, as described previously. 37 Infectious LV was harvested at 48 and 72 h posttransfection and filtered through 0.22-µm-pore cellulose acetate filters. The infectious LVs were concentrated by ultra centrifugation (2 h at 50,000 g) and subsequently purified by ultra centrifugation on a 20% sucrose gradient (2 h at 46,000 g).
Vector concentrations were analyzed using an immunocapture p24-gag enzyme-linked immunosorbent assay (Alliance; DuPont-NEN). To determine the infectious titer, 293T cells were plated in 24-well plates at a density of 1×10 5 cells/well and transduced with serial dilutions of LV.
Four days after inoculation, transduction efficiency was analyzed by FACS.
Construction of HIV-1-based LVs containing mutant capsid proteins.Capsid mutants were created by a site-directed mutagenesis (Stratagene, La Jolla, CA) of the packaging construct. The mutant constructs were subsequently sequenced to confirm the presence of mutations and exclude introduction of unwanted mutations. Mutant packaging constructs were used to produce LVs as described above.
Infection assays. 293T, CV-1, and FrhL2 cells were plated in 24-well plates at a density of 1×10 4 cells/well 24 h before inoculation. Cells were inoculated with different amounts of LV as indicated in the results. The number of infected cells was quantified by FACS analysis 4-6 days after inoculation. Where indicated, cells were treated with CsA (1 µg/ml; Sigma, St Louis, MO) starting 1 h before inoculation. In the coinfection experiments, 293T, CV-1, and FrhL2 cells were inoculated with 10 ng p24 of the LacZ-expressing LV containing the WT or mutant capsid protein and indicated concentrations of GFP-expressing LV containing WT or mutant capsid proteins. The effect of the coinfection on the infectivity of the WT or mutant LV was analyzed by FACS 4-6 days after inoculation.
PBMC were isolated from rhesus macaque blood or human buffy coat using ficoll density gradient centrifugation. PBMC were inoculated with GFP-expressing LV at a multiplicity of infection of 5 or 10 for 16 h. Subsequently, cells were washed and cultured in Iscove's modified Dulbecco's medium supplemented with 10% fetal calf serum (Hyclone, Logan, UT), 1 µg/ml phytohemagglutinin, antibiotic/antimycotic (Life Technologies, Rockville, MD) at a density of 1×10 5 per 100 µl. The percentage of GFP-expressing cells was determined by FACS analysis 6 days after inoculation.
